✦ LIBER ✦

Effect of (+)-Cyanidanol-3 in Acute HAV, HBV, and Non-A, Non-B Viral Hepatitis

✍ Scribed by Marcello Piazza; Vincenzo Guadagnino; Ludovico Picciotto; Renato De Mercato; Antonio Chirianni; Raffaele Orlando; Gerard Golden

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 497 KB
Volume: 3
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.1840030107

No coin nor oath required. For personal study only.

✦ Synopsis

A double-blind trial was carried out on 124 randomized patients with acute viral hepatitis, of whom 58 were treated with (+)-cyanidanol-3 in a dose of 3 g m per day and 66 with placebo. The treatment was given for 50 days. At 5-day intervals, SGPT, SGOT, and total serum bilirubin levels were tested. For the total group of patients, the levels of SGPT and SGOT activity were significantly lower in the cyanidanol group than in the control group from 30th to 50th day of treatment (with exception of SGOT at Day 35) (Student's t test: p between 0.01 and 0.05).

In 35 patients with acute hepatitis caused by hepatitis A virus, 17 treated with cyanidanol and 18 controls, no significant differences for either SGPT and SGOT were observed. In 58 patients with acute hepatitis caused by hepatitis B virus, 27 treated with cyanidanol and 31 controls, a trend in

📜 SIMILAR VOLUMES

Aetiology of acute sporadic non-A, non-B

Aetiology of acute sporadic non-A, non-B viral hepatitis in India

✍ Dr.(Mrs) V. A. Arankalle; L. P. Chobe; J. Jha; M. S. Chadha; K. Banerjee; M. O. 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 491 KB 👁 1 views

## Abstract Non‐A, non‐B (NANB) hepatitis viruses are now classified as hepatitis E (enterically transmitted) and hepatitis C (parenterally transmitted). India experiences a large number of epidemics of the enteric disease every year. In addition, about 70% of the sporadic cases among adults are al

(+)-Cyanidanol-3 in the Treatment of Acu

(+)-Cyanidanol-3 in the Treatment of Acute Viral Hepatitis: A Randomized Controlled Trial

✍ Hans Schomerus; Karl H. Wiedmann; Wolfgang Dölle; Herrmann Peerenboom; Georg Str 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 461 KB 👁 1 views

One-hundred sixty patients (81 cyanidanol, 79 placebo) were included in a double-blind placebo-controlled clinical trial to evaluate the effect of 3 gm (+)-cyanidanol-3 per day for 8 weeks on the clinical course of acute viral hepatitis and HBsAg elimination. Quantitative determination of HBsAg was

Patterns of antibodies to hepatitis C vi

Patterns of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis and their relationship to viral replication and liver disease

✍ Liliana Chemello; Daniela Cavalletto; Patrizia Pontisso; Flavia Bortolotti; Carl 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 490 KB 👁 1 views

ChemInform Abstract: Antiviral Agents. P

ChemInform Abstract: Antiviral Agents. Part 3. Discovery of a Novel Small Molecule Non-Nucleoside Inhibitor of Hepatitis B Virus (HBV).

✍ Ian T. Crosby; David G. Bourke; Eric D. Jones; Tyrone P. Jeynes; Susan Cox; Jona 📂 Article 📅 2011 🏛 John Wiley and Sons ⚖ 19 KB 👁 1 views

Occurrence of hepatitis E virus IgM, low

Occurrence of hepatitis E virus IgM, low avidity IgG serum antibodies, and viremia in sporadic cases of non-A, -B, and -C acute hepatitis

✍ J.-Z. Zhang; Stanley W.K. Im; S.H. Lau; T.N. Chau; S.T. Lai; S.P. Ng; Malik Peir 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

## Abstract Serum samples were taken from 57 patients with sporadic non‐A, ‐B, and ‐C (Non A, B, C) acute hepatitis at different times after onset of the disease and tested for the presence of the hepatitis E virus (HEV) RNA, IgM, and low avidity IgG antibodies. The viral antibodies were detected u